Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (US20160215011) 4-{4-[(1E)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1-en-1-yl]-2-methylbenzyl}-5-(propan-2-yl)-1H-pyrazol-3-yl beta-D glucopyranoside acetate

Office : United States of America
Application Number: 15026427 Application Date: 30.10.2014
Publication Number: 20160215011 Publication Date: 28.07.2016
Grant Number: 09573970 Grant Date: 21.02.2017
Publication Kind : B2
Prior PCT appl.: Application Number:PCTUS2014063161 ; Publication Number: Click to see the data
IPC:
C07H 17/02
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
H
SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
17
Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
02
Heterocyclic radicals containing only nitrogen as ring hetero atoms
CPC:
C07H 17/02
A61K 31/7056
C07D 221/20
C07D 231/14
C07D 309/06
C07B 2200/13
Applicants: Eli Lilly and Company
Inventors: Susan Marie Reutzel-Edens
Agents: Nelsen L Lentz
Priority Data:
Title: (EN) 4-{4-[(1E)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1-en-1-yl]-2-methylbenzyl}-5-(propan-2-yl)-1H-pyrazol-3-yl beta-D glucopyranoside acetate
Abstract: front page image
(EN)

The present invention provides a compound of Formula I or hydrate thereof, useful for the treatment of diabetes.

embedded image


Also published as:
UAa201603973CA2925128DOP2016000067IL244899CN105705509KR1020160067157
EA201690749EP3066108AU2014347065ID2017/05727MYPI 2016701635PH1/2016/500851
VN48279MA39019BR112016008428JP6197113TH170175IN201627009884
TN2016000112ES2703944WO/2015/069541